← All organizations
Highest phase reached
Phase 4
Timeline
1990s
- Jul 1, 1994
Omeros Corporation— Founded
2010s
- May 30, 2014
phenylephrine— Marketing Organization
Drugs by trial phase (16 distinct, 27 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (10 own, 0 via acquisition)
Indications
Studied for
- Atypical Hemolytic Uremic Syndrome
- Azotemia
- Calculi
- Cataract
- Glomerulonephritis, IGA
- Glomerulonephritis, Membranoproliferative
- Hemolysis
- Hemolytic-Uremic Syndrome
- Heroin Dependence
- Huntington Disease
- Kidney Calculi
- Kidney Diseases
- Lupus Nephritis
- Nephritis
- Nephrolithiasis
- Opioid-Related Disorders
- Schizophrenia
- Syndrome
- Thrombotic Microangiopathies
- Tobacco Use Disorder
- Urinary Calculi
- Urolithiasis
- Vascular Diseases
Marketed drugs (2)
Recent trials (47)
- NCT06209736OfficialPhase 2Mar 1, 2024
- NCT06209736Lead sponsorPhase 2Mar 1, 2024
- NCT06298955OfficialPhase 2Feb 19, 2024
- NCT06298955Lead sponsorPhase 2Feb 19, 2024
- NCT05855083Lead sponsorPhase 2May 1, 2023
- NCT05972967Lead sponsorPhase 2Mar 27, 2023
- NCT05972967Study directorPhase 2Mar 27, 2023
- NCT05889299Study directorPhase 1Dec 9, 2022
- NCT05889299Lead sponsorPhase 1Dec 9, 2022
- NCT04829799CollaboratorPhase 4Aug 31, 2021
- NCT03864133CollaboratorPhase 4Jul 31, 2019
- NCT03608033Lead sponsorPhase 3Feb 16, 2018
- NCT03205995Study directorPhase 3Feb 23, 2017
- NCT03205995Lead sponsorPhase 3Feb 23, 2017
- NCT02682407Lead sponsorPhase 2Feb 1, 2016
Details
- Founded
- Seattle, WA, US Jul 1, 1994
- Last known activity
- Dec 23, 2025